020 512 9111
  1. Home
  2. News items
  3. Fewer surgeries may be needed for bladder cancer thanks to new blood test

Fewer surgeries may be needed for bladder cancer thanks to new blood test

2 feb. 2023 17:00

Thanks to a new blood test, patients with bladder cancer may be able to circumvent a precautionary cystectomy after treatment with immunotherapy. Scientists at the Netherlands Cancer Institute have shown that a new technique can improve the prediction of whether the tumor will recur.  The findings by Jeroen van Dorp, Michiel van der Heijden, and Bas van Rhijn, in collaboration with the Cambridge-based company Inivata, have been published in the scientific journal Nature Medicine. 

In this study, the scientists analyzed the blood of patients with bladder cancer who had been treated with immunotherapy. The subjects were part of a high-risk group and had an increased chance of disease recurrence, which put them on the waitlist for bladder removal surgery as a precautionary measure.

  • De wetenschappers focusten zich bij hun onderzoek op het zogenoemd vrij circulerend DNA in het bloed van de proefpersonen. Dat zijn kleine stukjes DNA die door de bloedbaan bewegen. Soms zit daar ook gemuteerd DNA bij dat afkomstig is van een tumor.  “Een tumor heeft namelijk genetische veranderingen ten opzichte van het normale weefsel”, legt hoofdonderzoeker Michiel van der Heijden uit.  “Kankercellen laten kleine stukjes DNA in de bloedbaan en de urine los die afwijkend zijn van de rest van het DNA. Bij ons onderzoek hebben we gekeken of we bij deze patiënten nog tumor-DNA kunnen oppikken, en of we zo konden voorspellen of de tumor terug zou komen, of niet."

The scientists investigated the freely circulating DNA in the subjects' blood: small pieces of DNA that move through the bloodstream. Sometimes these contain mutated DNA from a tumor. "This is because a tumor has undergone genetic changes compared to normal tissue," explains principal investigator Michiel van der Heijden. "Cancer cells release small pieces of DNA into the bloodstream and urine that differ from the regular DNA. In our study, we investigated whether we could still trace tumor DNA in these patients and whether we could use these measurements to predict whether the tumor would return or not.

The results of the study are promising. Based on the results of the blood tests, the researchers were able to correctly predict whether patients would recover after immunotherapy in most cases. Small pieces of mutated DNA from the tumor were often found in patients who did not respond well to the therapy. In the patients who did respond well to the immunotherapy, no tumor DNA could be found in the blood after the treatment. This last group also saw significantly less tumor recurrence. "We seem to be able to predict the course of bladder cancer with great precision using this technique," says Van der Heijden. "That might help prevent radical surgery for a number of patients. Patients whose blood no longer contains tumor DNA may no longer need surgery at all.”

This is a major breakthrough because cystectomies are quite invasive. "The bladder is removed during surgery, which means that patients won’t be able to urinate normally anymore," he says. It does happen that no more tumor cells are found during surgery, indicating that the procedure may not have been necessary.

"With the tools we’ve had at our disposal thus far, we couldn’t determine whether people had really been cured," Van der Heijden explains. "No matter what kind of scans you use, you can't see exactly whether a tumor is completely gone after immunotherapy.

"This technique seems to bring improvement, and we may operate less often as a result. That's fantastic news. We will need to conduct the right follow-up studies, however, before we can apply this to clinical practice."

This website uses cookies

We use cookies on our website to improve the user experience.